更重要的是，决策者需要需要解决制药业金融化的问题，即只关注股东价值，而不是从所有相关利益者出发。
Even more to the point, policymakers need to address the financialization of the pharmaceutical industry, which is focused solely on shareholder value, rather than on all stakeholders.